Effect of Treatment With Stress-Doses Glucocorticoid in Patients With ARDS
Information source: Southeast University, China
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Acute Respiratory Distress Syndrome; Adrenal Insufficiency
Intervention: hydrocortisone (Drug); placebo (Drug)
Phase: Phase 4
Status: Not yet recruiting
Sponsored by: Southeast University, China
Summary
Stress doses of hydrocortisone improve early outcome in patients who is in early stage of
ARDS and with relative adrenal insufficiency.
Clinical Details
Official title: Effect of Treatment With Stress-Doses Glucocorticoid on Mortality in Patients With ARDS and Relative Adrenal Insufficiency
Study design: Treatment, Randomized, Single Blind (Subject), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Evidence of clinically definite ARDS confirmed by AECC criteria in 1994
Eligibility
Minimum age: 18 Years.
Maximum age: 85 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- within the first 3 days of onset of clinically definite ARDS confirmed by AECC
criteria in 1994
- 18 to 85 year old
Exclusion Criteria:
- pregnancy or lactation
- tumor or other immunologic disease
- immunosuppressive drug used
- bone marrow or lung transplantation
- primary or secondary disease of adrenal gland
- hormone used within 3 months
- refusing conventional therapy
- be in other clinical tests within 30 days
Locations and Contacts
Additional Information
Starting date: October 2008
Last updated: October 15, 2008
|
